Immune-related adverse events in patients with pre-existing autoimmune rheumatologic disease on immune checkpoint inhibitor therapy

Amanda Lusa; Carolina Alvarez; Shruti Saxena Beem; Todd A Schwartz; Rumey Ishizawar

doi:10.1186/s41927-022-00297-5

Immune-related adverse events in patients with pre-existing autoimmune rheumatologic disease on immune checkpoint inhibitor therapy

BMC Rheumatol. 2022 Nov 8;6(1):64. doi: 10.1186/s41927-022-00297-5.

Authors

Amanda Lusa¹, Carolina Alvarez², Shruti Saxena Beem², Todd A Schwartz³, Rumey Ishizawar⁴

Affiliations

¹ Division of Rheumatology, Allergy, and Immunology, University of North Carolina, Chapel Hill, NC, USA. amanda_lusa@med.unc.edu.
² Thurston Arthritis Research Center, University of North Carolina, Chapel Hill, NC, USA.
³ Department of Biostatistics, Gillings School of Global Public Health and Thurston Arthritis Research Center, University of North Carolina, Chapel Hill, NC, USA.
⁴ Division of Rheumatology, Allergy, and Immunology, University of North Carolina, Chapel Hill, NC, USA.

Abstract

Introduction: Immune checkpoint inhibitors (ICIs) enhance the immune system's ability to target and destroy cancer cells, but this non-specific immune overactivation can result in immune-related adverse events (irAEs). Patients with underlying autoimmune diseases were excluded from the original ICI clinical trials because of the theoretical risk of irAEs. This study aimed to evaluate the risk of irAEs in patients with pre-existing rheumatologic diseases on ICIs, impact of anti-rheumatic therapy on irAEs, and malignancy outcomes.

Methods: We performed a retrospective chart review of patients with a pre-existing rheumatologic diagnosis receiving ICIs at the University of North Carolina from 2014 to 2019. Risk differences (RD) and asymptotic 95% confidence intervals (95% CIs) using a continuity correction along with odds ratios (OR) and exact 95% CIs were produced between pre-specified risk factors and flares of the underlying rheumatologic disease and/or irAEs. Kaplan-Meier survival estimates for time to unfavorable cancer response between subsets of patients were compared using the log-rank test.

Results: We identified 45 patients receiving an ICI with an underlying rheumatologic diagnosis, including 22 with rheumatoid arthritis (RA). Overall, 13 patients (29%) had a flare of their autoimmune disease, 20 patients (44%) had a new-onset irAE, and 27 (60%) had either a flare or new-onset irAE. Patients with RA had higher risk of flares compared to those with other rheumatologic disorders (45% vs 13%, RD 32%, 95% CI 2.0-56.8); all RA flares were ≤ grade 2 and treated in the outpatient setting. Concurrent treatment of the rheumatologic disease at the start of ICI therapy was not associated with a reduced risk of flare (OR 0.86, 95% CI 0.19-3.76) or new onset irAE (OR 3.21, 95% CI 0.83-13.6) compared to those not on anti-rheumatic medications. Anti-rheumatic therapy did not impact time to unfavorable malignancy outcome (p = 0.52).

Conclusion: The majority of our study cohort experienced a flare or new onset irAE with ICI treatment. Treatment with anti-rheumatic therapy did not prevent disease flares or new onset irAEs, but did not negatively impact malignancy outcomes. Research is needed to determine safe anti-rheumatic therapy options to prevent flares and irAEs that do not interfere with malignancy outcomes.

Keywords: Anti-rheumatic therapy; Disease flare; Immune checkpoint inhibitor; Immune-related adverse event; Rheumatoid arthritis; Rheumatologic disease.

Abstract

Grants and funding